Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.5% - Should You Sell?

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) fell 6.5% during mid-day trading on Tuesday . The company traded as low as $9.83 and last traded at $9.99. 1,142,401 shares changed hands during trading, an increase of 37% from the average session volume of 834,875 shares. The stock had previously closed at $10.68.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on STOK. HC Wainwright upped their price target on Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a research report on Tuesday. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of "Buy" and an average price target of $23.00.

Stoke Therapeutics Stock Performance

The firm's 50 day moving average price is $10.62 and its 200-day moving average price is $12.32. The firm has a market capitalization of $441.24 million, a PE ratio of -3.97 and a beta of 0.95.

Insider Transactions at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 6,786 shares of the company's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now owns 61,885 shares in the company, valued at $803,886.15. This represents a 9.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the company's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now owns 47,332 shares of the company's stock, valued at approximately $604,902.96. This trade represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 in the last ninety days. 11.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. Bank of New York Mellon Corp raised its position in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after buying an additional 1,330 shares during the period. Graham Capital Management L.P. raised its position in shares of Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after buying an additional 1,453 shares during the period. Gilder Gagnon Howe & Co. LLC raised its position in shares of Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after buying an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after buying an additional 2,215 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.